It’s been 2 weeks since CEO Martin Shkreli promised to lower the price of AIDS drug Daraprim. It’s still the same price.

Martin Shkreli smirks during a television interview as he boasts about his decision to gouge patients.

Martin Shkreli smirks during a television interview as he boasts about his decision to gouge patients.

Martin Shkreli

Martin Shkreli

Tech Insider reports that two weeks after Turing CEO Martin Shkeli assured the world he would lower the price of his drug, nothing has actually changed.

Last month, Shkeli provoked outrage when it was revealed he planned to dramatically raise the price of Daraprim, a drug that helps fight parasitic infections.

The drug rose from $13.50 to $750; a 5000% price hike.

Speaking to ABC News last month, he said, “We’ve agreed to lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit.”

So far, that’s yet to happen.

The price hasn’t gotten any higher in recent days, but it hasn’t gotten any lower, either.

A 30-day supply purchased at your nearest pharmacy would cost you $27,006; roughly $900 a pill.

This Story Filed Under

Comments